ISTH: Apixaban non-inferior to conventional treatment for VTE

ISTH: apixaban non-inferior to conventional treatment for VTE
For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according to a study published online July 1 in the New England Journal of Medicine to coincide with presentation at the annual Congress of the International Society on Thrombosis and Haemostasis, held from June 29 to July 4 in Amsterdam.

(HealthDay)—For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according to a study published online July 1 in the New England Journal of Medicine to coincide with presentation at the annual Congress of the International Society on Thrombosis and Haemostasis, held from June 29 to July 4 in Amsterdam.

Giancarlo Agnelli, M.D., from the University of Perugia in Italy, and colleagues conducted a randomized double-blind study to compare apixaban with subcutaneous , followed by warfarin (conventional therapy) in 5,395 patients with acute venous thromboembolism.

The researchers found that the primary efficacy outcome of recurrent symptomatic venous thromboembolism or death related to venous thromboembolism occurred in 2.3 and 2.7 percent of patients in the apixaban and conventional-therapy groups, respectively (relative risk, 0.84; 95 percent confidence interval, 0.60 to 1.18; difference in risk, ?0.4 percentage points; 95 percent confidence interval, ?1.3 to 0.4). For predefined upper limits of the 95 percent confidence intervals for both relative risk and difference in risk, apixaban was non-inferior to conventional therapy. Major bleeding occurred in significantly fewer patients in the apixaban group (0.6 versus 1.8 percent; relative risk, 0.31). The composite outcome of major bleeding and clinically relevant non-major bleeding occurred in significantly fewer patients in the apixaban group (4.3 versus 9.7 percent; relative risk, 0.44).

"A fixed-dose regimen of apixaban alone was non-inferior to for the treatment of acute venous thromboembolism and was associated with significantly less bleeding," the authors write.

The study was funded by Pfizer and Bristol-Myers Squibb, the manufacturers of .

More information: Abstract
Full Text
Editorial
More Information

add to favorites email to friend print save as pdf

Related Stories

Prophylaxis with apixaban feasible for cancer patients

Mar 29, 2012

(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic ...

Proof of added benefit of apixaban in hip replacement

Sep 17, 2012

The clot-inhibiting drug apixaban (trade name: Eliquis) was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint. In an early benefit assessment pursuant to the ...

Recommended for you

Global Ebola toll rises to 5,689: WHO

1 hour ago

The World Health Organization said Thursday that the global death toll from the Ebola virus had increased to 5,689 out of a total of 15,935 cases of infection, mainly in western Africa.

Ebola vaccine promising in first human trials

11 hours ago

Researchers say they're a step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

At one month, US Ebola monitors finding no cases

14 hours ago

The U.S. program that requires weeks of monitoring for travelers from African countries with Ebola reaches the one-month mark Thursday. And so far, no cases of the disease have turned up.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.